News Feed Opinion Blog Posts Career Updates Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
AIM-HI Portfolio Company Yiviva Reports Promising Phase 2b Results for YIV-906
Photo: https://depositphotos.com
Jul 30, 2025, 18:22

AIM-HI Portfolio Company Yiviva Reports Promising Phase 2b Results for YIV-906

AIM-HI Accelerator Fund shared a post on LinkedIn:

“AIM-HI portfolio company Yiviva reports promising Phase 2b results!

At ASCO25 and ESMOGI25, Yiviva presented new data showing that YIV-906, when combined with sorafenib, significantly improves survival and tolerability for patients with advanced hepatocellular carcinoma and chronic hepatitis B.

Key findings:

  • Median overall survival nearly doubled
  • Improved tumor progression timelines
  • Better treatment tolerance

Backed by AIM-HI, NFCR, AFCR, and Yale, Yiviva is redefining cancer treatment by merging systems biology with centuries-old medicinal knowledge.

Read more.”

AIM-HI Portfolio Company Yiviva Reports Promising Phase 2b Results for YIV-906

More posts featuring AIM-HI Accelerator Fund.

AIM-HI Accelerator Fund ASCO25 cancer Chronic hepatitis B ESMOGI25 hepatocellular carcinoma OncoDaily Oncology Yiviva
Special Coverage
Voices
Aug 18, 2025, 17:43
Building a Healthier Future for Women Also Means Building a Healthier Future for the Next Generation - Elekta Foundation
Voices
Aug 18, 2025, 17:35
Mandar Muzumdar: The Evolution of Single-Cell 3D Genomes in KRAS-Driven Cancers
Blog Posts
Aug 18, 2025, 17:21
Douglas Flora: Create the Things You Wish Existed
Blog Posts
Aug 18, 2025, 17:13
Matt Yurgelun: Thrilled to Be Joining The Jimmy Fund Radio-Telethon
Voices
Aug 18, 2025, 17:04
Striking out Cancer for Patients Like Charlie - The Jimmy Fund
Insight
Aug 18, 2025, 16:52
Darren Haywood: Pleased to Receive COSA Endorsement of the MASCC COG-IMPACT Tool
Science
Aug 18, 2025, 16:48
Petros Grivas: Highlighting Intra-Patient Tumor Heterogeneity in Prostate Cancer Research
Science
Aug 18, 2025, 16:46
How Do We Select the Best 2L Therapy for Advanced EGFR‑Mutant NSCLC After Osimertinib? - Oncogene Cancer Research
Blog Posts
Aug 18, 2025, 16:37
Amanda Impellizzeri: What a Weekend at the Carolina Cancer Conference
Science
Aug 18, 2025, 16:33
Maria Tolia: New Study on Cardio-Oncology Considerations for Breast Cancer
Science
Aug 18, 2025, 16:25
The Findings from AICR and WCRF Research on World Breast Cancer Research Day
Voices
Aug 18, 2025, 16:10
Hung Trinh: Pfizer Completes Licensing Agreement with 3SBio